Same answer as semaglutide
37 Interpretation of these findings is constrained by potential underreporting of biliary outcomes and reliance on aggregate trial-level data rather than individual patient data
[They] have simply fluctuated between five to 10 pounds after a significant weight loss of 50 to 70 pounds. Because semaglutide is a peptide drug, and peptides are like messenger systems, Decotiis says the drug might be able to rewire appetite over time, giving people struggling with diabetes and weight loss a greater chance of improving their eating habits
The future oral GLP-1 receptor agonists, incretin dual agonists, triple agonists, and other new oral metabolic products will become popular only if they prove themselves capable of producing sustained results in obesity disease, type 2 diabetes, hypertension, dyslipidemia, cardiovascular risks, and metabolic syndromes through their effectiveness and safety
This is a mechanism-based concern, not a confirmed risk, but it would warrant HPA axis biomarkers (morning cortisol, ACTH) in a pediatric trial protocol